Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Saved in:
| Title: | Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. |
|---|---|
| Authors: | Dytfeld, Dominik1 (AUTHOR), Wróbel, Tomasz2 (AUTHOR), Jamroziak, Krzysztof3 (AUTHOR), Kubicki, Tadeusz1 (AUTHOR), Robak, Paweł4 (AUTHOR), Walter-Croneck, Adam5 (AUTHOR), Czyż, Jarosław6 (AUTHOR), Tyczyńska, Agata7 (AUTHOR), Druzd-Sitek, Agnieszka8 (AUTHOR), Giannopoulos, Krzysztof9 (AUTHOR), Nowicki, Adam1 (AUTHOR), Szczepaniak, Tomasz1 (AUTHOR), Łojko-Dankowska, Anna1 (AUTHOR), Matuszak, Magdalena1 (AUTHOR), Gil, Lidia1 (AUTHOR), Puła, Bartosz1 (AUTHOR), Rybka, Justyna2 (AUTHOR), Majcherek, Maciej2 (AUTHOR), Usnarska-Zubkiewicz, Lidia2 (AUTHOR), Szukalski, Łukasz6 (AUTHOR) |
| Source: | Lancet Oncology. Feb2023, Vol. 24 Issue 2, p139-150. 12p. |
| Database: | Academic Search Ultimate |
| ISSN: | 14702045 |
|---|---|
| DOI: | 10.1016/S1470-2045(22)00738-0 |
